LOS ANGELES--(EON: Enhanced Online News)--Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Endologix Inc. (“Endologix” or the “Company”) (Nasdaq: ELGX) concerning possible violations of federal securities laws. Investors who purchased or otherwise acquired Endologix shares between August 2, 2016 and November 16, 2016 inclusive (the “Class Period”), are encouraged to contact the firm in advance of the March 6, 2017 lead plaintiff motion deadline.
No class has been certified in the above action yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.
Endologix’s endovascular aneurysm sealing system for treating infrarenal abdominal aortic aneurysms is Nellix. Endologix noted that it would approve the original Nellix system used in the Nellix investigational device exemption (IDE) clinical trial, the EVAS FORWARD-IDE Study. However, Endologix disclosed that the FDA requested a follow-up on patients in the EVAS-FORWARD-IDE study to evaluate Nellix.
On December 27, 2016 Endologix stated that it was temporarily barring AFX Endovascular AAA System shipments, due to a manufacturing investigation. Upon disclosing this information to the investing public, Endologix stock fell sharply, causing shareholders severe harm.
Lundin Law PC was established by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders' rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.